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Abstract
Background: Packed red blood cell (PRBC) transfusion is required in hematology patients treated with chemotherapy
for acute leukemia, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). In certain
situations like septic shock, hip surgery, coronary disease or gastrointestinal hemorrhage, a restrictive transfusion
strategy is associated with a reduction of infection and death. A transfusion strategy using a single PRBC unit has been
retrospectively investigated and showed a safe reduction of PRBC consumption and costs. We therefore designed a
study to prospectively demonstrate that the transfusion of a single PRBC unit is safe and not inferior to standard care.
Methods: The 1versus2 trial is a randomized trial which will determine if a single-unit transfusion policy is not inferior
to a double-unit transfusion policy. The primary endpoint is the incidence of severe complication (grade ≥ 3) defined as
stroke, transient ischemic attack, acute coronary syndrome, heart failure, elevated troponin level, intensive care unit
transfer, death, new pulmonary infiltrates, and transfusion-related infections during hospital stays. The secondary
endpoint is the number of PRBC units transfused per patient per hospital stay. Two hundred and thirty patients will be
randomized to receive a single unit or double unit every time the hemoglobin level is less than 8 g/dL. All patients
admitted for induction remission chemotherapy, auto-HSCT or allo-HSCT in hematology intensive care units will be
eligible for inclusion. Sample size calculation has determined that a patient population of 230 will be required to prove
that the 1-unit PRBC strategy is non-inferior to the 2-unit PRBC strategy. Hemoglobin threshold for transfusion is below
8 g/dL. Estimated percentage of complication-free hospital stays is 93 %. In a non-inferiority hypothesis, the number of
patients to include is 230 with a power of 90 % and an alpha risk of 5 %.
Trial Registration: 14–128; Clinicaltrials.gov NCT02461264 (registered on 3 June 2015)
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Background
Transient anemia is a common complication of
hematological malignancy treatment or following
hematopoietic stem-cell transplantation (HSCT). Red
blood cells and platelet supports remain a significant
part of the treatment of patients receiving chemotherapy
for acute leukemia or HSCT conditioning. Historically,
two packed red blood cell (PRBC) units are transfused at
once. Transfusion triggers are either prophylactic, with a
hemoglobin threshold varying between 7 and 8 g/dL ac-
cording to the country in question, or therapeutic in case
of symptomatic anemia. In different situations, like septic
shock, hip surgery, chronic coronary disease or gastro-
intestinal bleeding, several trials have demonstrated that a
less restrictive strategy, using a lower prophylactic transfu-
sion trigger was better than a more liberal one. This strat-
egy significantly reduced transfusion-related infections,
cardiac complications and the number of PRBC units used
[1–4]. In patients with induced hematological toxicities,
no prospective randomized trial supports the restrictive
strategy. In the context of HSCT, a randomized controlled
trial comparing 2 hemoglobin thresholds as trigger for red
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blood cell transfusion (12 g/dL in the experimental arm
and 7 g/dL in the standard arm) has been prematurely
closed because of an excess of veno-occlusive disease in
the experimental group supporting the restrictive strategy
arm [5]. Berger et al. have demonstrated in a retrospective
study that the transfusion of 1 unit instead of 2 units in
hematological malignancy patients resulted in a significant
reduction of about 25 % of PRBC units transfused without
increasing symptomatic anemia or side effects [6]. In a
retrospective pilot study, we also demonstrated the feasi-
bility of this restrictive strategy with a reduction of PRBC
units transfused [7].
To date, there is no high-level evidence to support the
use of one-unit transfusion in hematological practice,
even if a single-unit transfusion is recommended, and
could be now considered as a standard of care in a num-
ber of clinical situations as in cases of chronic heart fail-
ure, in older-aged and in critically ill patients [8].
We also need a trial with high-level evidence to reduce
the number of transfusions and the cost of hospitalization.
If the single-unit policy proves to be non-inferior com-
pared to the standard of care, it would change decennials’
years of practice for a large number of patients. If it re-
duces the cost of hospitalization, the economic impact
would be very important for the wider society.
Objective
The aim of the study is to demonstrate, in a prospective
non-inferiority randomized study in a selective popula-
tion of patients receiving chemotherapy in an intensive
hematological unit, that a strategy using a single-unit
transfusion is non-inferior to a two-unit transfusion in




This is a prospective, multicenter, two-arm random-
ized study. The study will be held in an intensive care
hematological ward of three hospitals (Amiens, Caen
and Rouen). The transfusion of a single PRBC unit
(1PRBC arm – arm B) per day in case of symptomatic
anemia or hemoglobin level below 8 g/dL will be com-
pared to the standard strategy of using a transfusion of
2 PRBC units at once (2PRBC arm – arm A).
Study population
Eligible patients are adults (≥ 18 years) hospitalized in an
intensive hematological ward for remission-induction
chemotherapy, auto-HSCT or allo-HSCT with a predict-
able need for PRBC transfusion.
Exclusion criteria are the following: acute promyelocytic
leukemia, known ischemic heart disease, acute or chronic
respiratory disease, history of ischemic stroke, disseminated
intravascular coagulation, hemorrhagic syndrome, HSCT
conditioning not usually associated with PRBC transfusion
need such as auto-HSCTconditioned with alkeran (myeloma
patients), non-myelo-ablative allo-HSCT conditioned using
only fludarabine and total body irradiation (TBI) 2 gray,
erythropoietin treatment, autoimmune hemolytic anemia,
pregnancy, renal impairment with an estimated (modified diet
in renal disease; MDRD) creatinine clearance< 50 ml/min,
chronic liver disease or day-1 (AST/ALT )≥ 2.5 upper limit of
normal (ULN) (except in leukemic disease), total bilirubin≥1.5
ULN, cirrhosis, age <18 years, or any organ failure.
Consent and ethical consideration
The study protocol and information forms were ap-
proved by the competent French legal authority (Comité
de Protection des Personnes Nord Ouest III, registration
number: 2014-A01473-44; date of approval 5 January
2015). Patients will be informed verbally and provided
with a written document about the 1versus2 study by
the investigators. Patients will be informed about the
trial and their right to refuse participation. Informed
consent will be signed by each participant.
Randomization
Randomization codes have been generated and secured
by an independent statistician from Centre Hospitalier
Universitaire of Caen. The codes have been made avail-
able to a Good Manufacturing Practice (GMP) certified
clinical trial supply company, which has prepared the
treatment packs in accordance with the randomization
list. The randomization will be stratified by center and
reason for hospitalization.
Treatment and study intervention
The study protocol and both arms of randomization are de-
tailed in Fig. 1. Patients randomized in arm A will receive 2
PRBC units if their hemoglobin level is below 8 g/dL during
hospitalization and until 1 month after discharge. Patients
randomized in arm B (experimental arm) will receive a sin-
gle PRBC unit if their hemoglobin is below 8 g/dL during
hospitalization and until 1 month after discharge. All PRBC
units are leukodepleted, and matched according to French
policies. Auto-SCT patients will receive irradiated PRBC
units and allo-SCT recipients cytomegalovirus (CMV) sero-
negative irradiated PRBC units [8].
Data collection and follow-up
Details of the flowchart and patient follow-up are sum-
marized in Table 1. Each subject who meets the inclu-
sion criteria, verified by the clinician investigator in
charge of medical care, will be offered the opportunity
enter the study during a meeting in consultation or at first
day of hospitalization. The investigator will retrieve the pa-
tient consent form at day zero. The following data will be
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collected at inclusion: vital signs (heart rate, arterial blood
pressure, and respiratory rate), weight, and abnormal
clinical signs on examination. Quality of Life in Cancer
Patients-30 (QLC30), Functional Assessment of Cancer
Therapy (FACT) form and EuroQol 5 dimensions (EQ-5D)
data will be collected and an electrocardiogram will be per-
formed at inclusion, the end of hospitalization stay and at 1
month after discharge. Creatinine level, blood count and
troponin blood level will be collected at inclusion. During
the hospitalization stay, blood count and transfusion data
will be collected every day until discharge. At the end of
the study (1 month follow-up), vital status, and the number
of RBP transfused after leaving the hospital and the dur-
ation of hospital stay will be recorded. Each complication
encountered en route to meeting the primary endpoint will
also be recorded.
A cost-effectiveness analysis will be performed alongside
the clinical evaluation. By reference to Haute Autorité de
Santé (HAS) guidelines [9], a collective perspective will be
adopted. The following costs will be included: blood trans-
fusions, initial hospital stay, transportation and manage-
ment of complications (primary endpoint). Costs will be
Fig. 1 Overview of the study protocol design
Table 1 Flowchart of a patient follow-up
Screening D-28
to D-1
DO inclusion At each transfusion End of hospitalization One month after hospitalization
Inclusion and exclusion criteria X
Patient information X
Signed informed consent X
QLC30, FACT, EQ-5D questionnaires X X X
Randomization X
Clinical assessment X X X
ECG X
Laboratory tests – troponin X
Biological tests X daily X X
Transfusion parameters X
Complications/Adverse events X
Alive or dead status X
EQ-5D EuroQol 5 dimensions, FACT Functional Assessment of Cancer Therapy, QLC30 Quality of Life in Cancer Patients-30,D-28 to D-1: day-28 to day -1
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collected prospectively over the 1-month follow-up period.
Survival and quality of life data collected alongside the
clinical trial will be used for Quality-adjusted Life Year
(QALY) computation with the validated French value
set [10].
Organization of the trial
Funding and support
The 1versus2 trial is supported by the Groupement Inter-
régional de Recherche Clinique et d’Innovation (GIRCI)
Nord-Ouest (Appel Offre Innovation 2014).
Blinding
Given the nature of the interventions, physicians, nurses,
and patients cannot be blinded for the randomized inter-
vention. A blinded adjudication committee will be con-
ducted to confirm each endpoint.
Study outcomes
Primary endpoint
The primary endpoint measure is the percentage of pa-
tients without complication at the end of hospitalization
in both arms. Complications are defined as: stroke, transi-
ent ischemic attack, acute coronary syndrome or elevated
troponin, heart failure, arrhythmias or heart conduction
disorder, deep vein thrombosis, pulmonary embolism,
transfer to intensive care unit, death from any cause, new
or progressive radiographic infiltrates, and transfusion-
related infections.
Secondary endpoints
Secondary endpoints are the of number of PRBC trans-
fused up to 1 month after discharge, cost-effectiveness
analysis; the number of patients with grade 3 or 4
bleeding, the number of patients with each complication
defined in the primary endpoint, the number of transfu-
sion- related events, number of days with hemoglobin
level > 8 g/dL quality of life, duration of neutropenia, the
time from randomization to last transfusion, the difference
between the hemoglobin level immediately before and the
day after transfusion, and the number of transfusion events
without respect of the randomization arm. Transfusion-
related events are defined as any complication declared by
the physician to be related to the transfusion (fever, infec-
tion, pulmonary edema, etc.). Quality of life will be
assessed using the FACT and QLC30 questionnaires. Neu-
tropenia duration is the time spent with an absolute neu-
trophil count < 0.5 109/L.
Statistical method
Sample size calculation
The goal of the study is to demonstrate the non-inferiority
of the experimental arm compared with the control arm
in terms of complication. Based on the hypothesis of 93 %
of hospitalizations without severe complication [2] and a
non-inferiority margin of 10 % in the single-unit group, a
total of 230 subjects (115 per group) should be random-
ized to provide a study power of 90 % with an alpha risk
of 5 %.
Methodology of the statistical analysis
The number of eligible patients and the number of pa-
tients actually included (total and per arm) will be de-
scribe in a chart. Qualitative variables will be described
as number and percentage, and quantitative variables as
number, mean, and standard deviation. Quantitative var-
iables with skewed distribution will be presented as me-
dian and interquartile range (25th percentile to 75th
percentile). The analysis for the primary endpoint will be
conducted in both, intent-to-treat and per-protocol data-
sets. The difference between randomized arms regarding
the primary endpoint will be computed with the corre-
sponding 95 % confidence interval and the appropriate
bound will be compared with the non-inferiority margin.
All analyses will be stratified by center and reason for
hospitalization (blocking factors). If non-inferiority of
the experimental arm over the control arm is demon-
strated in both the intent-to- treat and per-protocol ana-
lyses, superiority tests will eventually be conducted.
Other analysis
Categorical variables will be compared using the χ2 or
Fisher’s test, as appropriate. Continuous variables will be
compared using Student’s t test or the Wilcoxon test, as
appropriate. The analysis of the overall survival will be
adjusted for important stratification and prognostic fac-
tors using a multivariate analysis (Cox model). All sec-
ondary analyses will be conducted at the bilateral alpha
risk of 5 %. Analyses will be performed with SAS version
9.2 (SAS Institute Inc., Cary, NC, USA).
Recruitment and participating centers
A total of four French intensive hematological wards have
agreed to be part of this study. All study sites have medical
and paramedical teams who are experienced in the field of
hematological malignancy, bone marrow transplantation
and transfusion.
Discussion
When and how to transfuse patients in intensive care
and hematology units remains a key question. Several
meta-analysis have been performed in the context of
hemorrhagic syndrome, surgery, coronary syndrome,
and septic shock. These studies demonstrated that a re-
strictive transfusion strategy was associated with a reduc-
tion of the number of PRBC transfused, as compared to a
liberal strategy. This restrictive transfusion strategy was not
inferior to the liberal one in terms of mortality, overall
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morbidity and myocardial infarction. In hematological ma-
lignancies, one pilot prospective randomized trial and one
retrospective study have compared bleeding events and the
number of blood units used with liberal (trigger 12 g/dL)
and restrictive ones (8 g/dL). These studies evidenced a re-
duction of PRBC units transfused in the restrictive arm
[11, 12]. Another way to reduce transfusion side effects
and the number of transfusions is to reduce the number of
RBP transfused at each transfusion in patients with a po-
tential hematological recovery. The single-unit transfusion
strategy is not suitable for patients with chronic anemia
due to bone marrow failure or myelodysplastic syndrome
without therapy. In a retrospective study, Berger et al. dem-
onstrated a 25 % PRBC unit reduction with a substantial
cost saving in the intensive care hematology area with a
single-unit transfusion strategy compared to historical two
units per transfusion [6]. However, no prospective ran-
domized trials have ever been conducted to compare
these two strategies (single-unit versus double-unit trans-
fusion), based on the volume transfused rather than on a
hemoglobin level trigger. Another question that arises is
the duration of the lower hemoglobin level experienced by
the group receiving a single PRBC unit. Here, one can
argue that patients may experience greater fatigue in this
group with a consequent negative impact on quality of life.
Therefore, among secondary endpoints of the study, qual-
ity of life will be assessed to compare fatigue between the
two arms. The aim of this study is to provide a high level
of evidence as to whether a single-unit transfusion in pa-
tients with transient bone marrow failure is feasible, safe
and reduces patient care costs.
Trial status
Enrollment will start in September 2015 and is expected
to be completed in September 2017.
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